Bristol Myers Squibb reveals groundbreaking Camzyos data at ACC 2026

Bristol Myers Squibb has unveiled new clinical and real-world findings on Camzyos at the American College of Cardiology's (ACC) 2026 conference. The drug, already approved in over 60 countries, continues to reshape treatment for obstructive hypertrophic cardiomyopathy (oHCM). Key studies, including the first Phase 3 trial in adolescents, will be presented in detail.

Camzyos (mavacamten) is the first cardiac myosin inhibitor to gain widespread approval, including in the U.S. and EU. It targets the root cause of oHCM—hypercontractility—reducing obstruction in the left ventricle while improving energy efficiency and cardiac function.

At ACC 2026, full results from the SCOUT-HCM study will be shared. This Phase 3 trial marks the first assessment of a cardiac myosin inhibitor in adolescents with oHCM. Alongside this, findings from DISCOVER-HCM, MARVEL-HCM, and COMPASS-HCM will further demonstrate the drug's impact across different patient groups. New real-world analyses also confirm Camzyos's consistent safety and effectiveness in adults. In the U.S., it is currently prescribed for adults with symptomatic NYHA class II-III oHCM to enhance functional capacity and ease symptoms. The drug's long-term data have already set a new benchmark in oHCM care.

The latest presentations reinforce Camzyos's role as a transformative therapy for oHCM. With approvals spanning five continents and growing evidence from trials and real-world use, the drug is now a cornerstone of treatment. Further insights from ACC 2026 will likely expand its application in younger patients.